Treatment Adherence of Anti-TNF Drugs in the Patients with Inflammatory Bowel Disease: A Scale Development Study

被引:0
|
作者
Basak, Nur [1 ]
Uran, Berna Nilgun Ozgursoy [2 ]
Yuksel, Elif Saritas [3 ]
机构
[1] Izmir Katip Celebi Univ, Inst Hlth Sci, Internal Med Nursing Dept, Izmir, Turkey
[2] Izmir Katip Celebi Univ, Fac Hlth Sci, Izmir, Turkey
[3] Izmir Katip Celebi Univ, Med Sch, Izmir, Turkey
来源
TURKISH JOURNAL OF GASTROENTEROLOGY | 2022年 / 33卷 / 04期
关键词
Anti-TNF alpha; IBD; reliability; scale development; treatment compliance; validity; MEDICATION ADHERENCE; THERAPY; NONADHERENCE; RISK;
D O I
10.5152/tjg.2022.211170
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: This work studies the validity and reliability of the Anti-TNF Alpha Treatment Adherence Scale, which has newly been developed to measure the compliance of inflammatory bowel disease patients using the anti-TNF alpha agents that are widely used in gastroenterology and rheumatology clinics. Methods: The study group consisted of 165 irritable bowel disease patients aged 18 years and above who were using anti-TNF alpha drugs. After creating a question pool with 40 items, the pilot study was applied with 70 patients. SPSS 25.0 and AMOS programs were used. item-total correlation coefficients, Cronbach's alpha and test-retest analysis, missing data, extreme value, normality, 27% sub-upper item discrimination analysis, and exploratory and confirmatory factor analyses were used. Results: The factor structure of the scale was examined with exploratory and confirmatory factor analyses and the contribution of these components to the total variance was measured as 74.21%. The Anti-TNF Alpha Treatment Adherence Scale was found in relation to the scale structure consisting of 12 items and 4 sub-dimensions. According to the first level multifactorial analysis results, the goodness of fit identities of the scale were found at an acceptable level, with the following values: RMSEA 0.067; GFI 0.92; AGFI 0.87; CFI 0.95; and chi(2) 79.876 (P = .000). Conclusion: It was determined that the Anti-TNF Alpha Treatment Adherence Scale represents the area to be measured, measures the researched structure, has a high internal consistency between items, is interrelated, and is consistent over time. As a result of all measurements, it was determined that it is a valid and reliable scale.
引用
收藏
页码:336 / +
页数:12
相关论文
共 50 条
  • [1] AN AUDIT OF ADHERENCE TO ANTI-TNF THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Duncan, J.
    Sastrillo, M.
    Baker, J.
    Younge, L.
    Anderson, S.
    Lindsay, J.
    Sanderson, J.
    Irving, P.
    GUT, 2011, 60
  • [2] Inflammatory bowel disease after anti-TNF drugs
    Hamilton, Louise
    Griffin, Jane
    Dahiya, Sandeep
    Somerville, Margaret
    Stodell, Malcolm
    RHEUMATOLOGY, 2008, 47 : II18 - II18
  • [3] Anti-TNF Treatment in Inflammatory Bowel Disease
    Yapali, Suna
    Hamzaoglu, Hulya Over
    ANNALS OF GASTROENTEROLOGY, 2007, 20 (01): : 48 - 53
  • [4] Adherence to Anti-TNF Therapy in Outpatients With Inflammatory Bowel Disease
    Have, Mike V.
    Oldenburg, Bas
    Kaptein, Adrian A.
    Siersema, Peter D.
    Fidder, Herma
    GASTROENTEROLOGY, 2013, 144 (05) : S199 - S200
  • [5] Anti-TNF Treatment in Inflammatory Bowel Disease Patients Diagnosed in Adolescence
    Naik, Amar S.
    Asamoah, Nikiya
    Zadvornova, Yelena
    Perera, Lilani P.
    Stein, Daniel J.
    Saeian, Kia
    Venu, Nanda
    GASTROENTEROLOGY, 2012, 142 (05) : S362 - S362
  • [6] Optimizing anti-TNF treatment in inflammatory bowel disease
    Rutgeerts, P
    Van Assche, G
    Vermeire, S
    GASTROENTEROLOGY, 2004, 126 (06) : 1593 - 1610
  • [7] Are anti-TNF drugs safe for pregnant women with inflammatory bowel disease?
    Brennan, Gregory T.
    Duong, Alex
    Nguyen, Emily T.
    Nguyen, Douglas L.
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2018, 85 (12) : 923 - 924
  • [8] Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease
    Orfanoudaki, Eleni
    Foteinogiannopoulou, Kalliopi
    Theodoraki, Eirini
    Koutroubakis, Ioannis E.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (07)
  • [9] Anti-TNF Treatment and Risk of Atrial Fibrillation in Inflammatory Bowel Disease Patients
    Cohen, Y.
    Fischman, M.
    Waterman, M.
    Dolnikov, K.
    Azzam, Z. S.
    Ghersin, I.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 681 - 681
  • [10] Serious pulmonary infections in patients with inflammatory bowel disease on treatment with anti-TNF
    Algaba, A.
    Guerra, I.
    Guardiola, A.
    Bonillo, D.
    Granja, A.
    Bernal, P.
    Aller, M. d. M.
    Hernandez, B.
    Aullo, C.
    Bermejo, F.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S521 - S522